African Journal of Infectious Diseases Research

ISSN 2756-3340

African Journal of Infectious Diseases Research | Vol. 12, No. 6, June 2025 | pp. 067–077

DOI: 10.46882/AJIDR/148787

Article Type: Research Article

Title: Prevalence and clinical impact of Epstein-Barr virus reactivation among patients with hematological malignancies undergoing chemotherapy

Names of Authors: Kwame Boateng¹*, Elena Petrova², Lucas Moretti³

Authors’ Affiliations: ¹Department of Hematology, University of Ghana, Accra, Ghana. ²Department of Oncology, Saint Petersburg State University, Saint Petersburg, Russia. ³Department of Clinical Virology, University of Milan, Milan, Italy.

Abstract: Epstein-Barr virus reactivation during cytotoxic chemotherapy can trigger febrile neutropenia and lymphoproliferative complications in immunocompromised oncology patients. We evaluated the incidence, viral load dynamics, and clinical outcomes of Epstein-Barr virus reactivation among adults receiving induction chemotherapy. Serial plasma specimens from 210 patients with leukemia or lymphoma were quantified using real-time polymerase chain reaction. Significant viral reactivation occurred in 23.8 percent of patients and correlated with prolonged neutropenic fever and delayed chemotherapy cycles. Severe lymphopenia and steroid-containing regimens independently predicted reactivation. Preemptive viral load monitoring is advised for high-risk hematology patients.

Keywords: Epstein-Barr virus, Viral reactivation, Hematological malignancies, Chemotherapy, Febrile neutropenia

Citation: Boateng K, Petrova E, Moretti L (2025). Prevalence and clinical impact of Epstein-Barr virus reactivation among patients with hematological malignancies undergoing chemotherapy. African Journal of Infectious Diseases Research, 12(6): 067–077. DOI: 10.46882/AJIDR/148787

Manuscript Timeline: Received: April 30, 2025; Revised: June 01, 2025; Accepted: June 13, 2025; Published: June 23, 2025